Summary: 1-Aminobenzotriazole (ABT) is widely used as a non-speciˆc inhibitor of animal cytochrome P450 (CYP). In the present study, the inhibitory eŠect of ABT was investigated on drug oxidations catalyzed by human CYP isoforms. This inhibitory eŠect was compared with that of SKF-525A, another non-speciˆc inhibitor, and ketoconazole, a potent inhibitor of CYP3A. Bacurovirus-expressed recombinant human CYP isoforms were used as an enzyme source. The speciˆc activities for human CYP isoforms are: phenacetin O-deethylation, for CYP1A2; diclofenac 4?-hydroxylation, for CYP2C9; S-mephenytoin 4?-hydroxylation, for CYP2C19; bufuralol 1?-hydroxylation, for CYP2D6; chlorzoxazone 6-hydroxylation, for CYP2E1; testosterone 6b-hydroxylation, nifedipine oxidation, and midazolam 1?-hydroxylation, for CYP3A4. ABT inhibited both CYP1A2-dependent activity (Ki＝330 mM) and CYP2E1-dependent activity (Ki＝8.7 mM). In contrast, SKF-525A weakly inhibited CYP1A2-dependent activities (46z inhibition at 1200 mM) and CYP2E1-dependent activities (65z inhibition at 1000 mM). ABT exhibited the highest Ki value for CYP2C9-dependent diclofenac 4?-hydroxylation among those determined by this assay (Ki＝3500 mM). Moreover, SKF-525A showed strong inhibition of CYP2D6-dependent bufuralol 1?-hydroxylation (Ki＝0.043 mM). Ketoconazole inhibited all tested drug oxidations, however, its inhibitory eŠect on CYP1A2-dependent activities was very weak (50z inhibition at 120 mM). ABT, SKF-525A, and ketoconazole showed diŠerent selectivity and had a wide range of Ki values for the drug oxidations catalyzed by human CYP enzymes. Therefore, we conclude that inhibitory studies designed to predict the contribution of CYP enzymes to the metabolism of certain compounds should be performed using multiple CYP inhibitors, such as ABT, SKF-525A, and ketoconazole.
Introduction
The cytochrome P450 (CYP) enzyme consists of a superfamily of haem-containing monooxygenase associated with the metabolism of substrates, such as drugs, environmental pollutants and endogenous substrates with broad overlapping substrate speciˆcities. 1) CYPs are membrane-bound enzymes that exist mainly in the liver, but they are also found in extrahepatic tissues, such as intestine, lung and kidney. 2) In human, xenobiotics are metabolized primarily by three CYP families; namely, CYP1, CYP2, and CYP3.
3) CYP enzymes play an important role in the drug metabolic pathway, one of the major clearance routes. Therefore, predicting the contribution of CYP enzymes to metabolic reactions in human liver microsomes is very important in the drug development process.
1-Aminobenzotriazole (ABT) is known to be a mechanism-based inhibitor (Fig. 1) . It has been reported that incubating rat liver microsomes with 10 mM ABT results in an 81z loss of CYP activity. 4) The inhibitory eŠect of ABT has been investigated in animal liver and lung microsomes from rat, rabbit, and guinea pig. [5] [6] [7] However, this eŠect has not been investigated in human liver microsomes. It should be noted that CYP enzymes show interspecies variation in their expression and catalytic activities.
In this study, we investigated the inhibitory eŠect of ABT on drug oxidations catalyzed by human CYP isoforms. This inhibitory eŠect was compared with that of SKF-525A, another non-speciˆc inhibitor, and ketoconazole, a potent inhibitor of CYP3A (Fig. 1) . We selected six isoforms which play a signiˆcant role in drug oxidations: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. The metabolic system of CYP3A4 is complicated by the presence of homotropic and heterotropic cooperativities with some substrates, but not all of them. 8) Wang et al. reported that testosterone did not inhibit nifedipine oxidation, although nifedipine did inhibit testosterone 6b-hydroxylation in human liver microsomes in a concentrationdependent manner. 9) In addition, Kenworthy et al. reported four distinct categorized groups for CYP3A4 substrates based on their mutual inhibitory potencies: (1) erythromycin and testosterone, (2) diazepam and midazolam, (3) terfenadine, and (4) nifedipine. 10) According to Kenworthy et al., nifedipine forms a separate group simply because it has diŠerent relationship from the other CYP3A4 substrates, so it forms aǹ`o ther'' groups. This report also recommended that multiple CYP3A4 probes should be used for the in vitro evaluation of CYP3A4-dependent drug interactions. Based on theˆndings in these reports, testosterone, nifedipine, and midazolam were selected as the CYP3A substrates for this study. Enzyme assays: Enzyme assay was conducted automatically using TECAN genesis systems (TECAN Schweiz AG, Hombrechtikon, Switzerland). The following oxidations were selected as probe reactions: phenacetin O-deethylation by CYP1A2, diclofenac 4?-hydroxylation by CYP2C9, S-mephenytoin 4?-hydroxylation by CYP2C19, bufuralol 1?-hydroxylation by CYP2D6, chlorzoxazone 6-hydroxylation by CYP2E1, and testosterone 6b-hydroxylation, nifedipine oxidation, and midazolam 1?-hydroxylation by CYP3A4. For each of the above oxidations, the standard incubation mixture consisted of 3.3 mM MgCl2, 100 mM sodium potassium phosphate buŠer (pH＝7.4), recombinant CYP protein, and substrate, in the presence and absence of inhibitors. The CYP concentrations were as follows; CYP1A2, 0.19 mg W mL; CYP2C9, 0.016 mg W mL; CYP2C19, 0.12 mg W mL; CYP2D6, 0.021 mg W mL; CYP2E1, 0.067 mg W mL; and CYP3A4, 0.049 mg W mL. The reaction was initiated by adding an NADPH (ˆnal 1 mM) after preincubation for 10 min in water bath at 379 C. After incubation for 10 min at 379 C, the reaction was terminated by the addition of acetonitrile, which contained an internal standard. After the removal of proteins by centrifugation at 2,000 rpm for 15 min at 49 C, the supernatant LC W MS W MS analysis: All measurements were performed by LC W MS W MS in the multiple reaction monitoring (MRM) mode. The mode for electrospray ionization and the transitions of m W z, namely m W z of the protonated W deprotonated molecular ion and predominant production, are summarized in Table 1 .
LC W MS W MS for phenacetin O-deethylation was performed using an API-4000 mass spectrometer (Applied Biosystems W MDS SCIEX, Toronto, Canada) and a 1100 series HPLC system (Agilent Technologies, Taufkirchen, Germany) equipped with a Wakosil-II 5C18 HG column (2×50 mm; 5 mm, Wako Pure Chemical Industries Ltd). The ‰ow rate of mobile phase was 0.40 mL W min and the column temperature was 409 C. The mobile phases were consisted of solvent A (10z (v W v) acetonitrile containing 10 mM ammonium acetate) and solvent B (80z (v W v) acetonitrile containing 10 mM ammonium acetate). Typical conditions for elution were as follows: 0z B (0.0¿0.1 min); 0 to 100z B (0.1¿1.5 min); 100z B (1.5¿3.0 min); and 100 to 0z B (3.0¿3.1 min).
LC W MS W MS for S-mephenytoin 4?-hydroxylation and testosterone 6b-hydroxylation was performed using the API-4000 mass spectrometer and the 1100 series HPLC system equipped with an Atlantis TM dC18 column LC W MS W MS was performed using an API-3000 mass spectrometer and the 1100 series HPLC system equipped with a YMC polymer C18 column (2×75 mm; 6 mm, YMC, Kyoto, Japan) for diclofenac 4?-hydroxylation and chlorzoxazone 6-hydroxylation and a YMC ODS L-80 column (2×75 mm; 4 mm, YMC) for bufuralol 1?-hydroxylation, nifedipine oxidation, and midazolam 1?-hydroxylation. The ‰ow rate was 0.35 mL W min. The column temperature and the mobile phases were the same as described in the detection methods for phenacetin O-deethylation. Typical conditions for elution of nifedipine oxidation sample were as follows: 0 to 100z B (0.0¿2.5 min); 100z B (2.5¿ 5.5 min); and 100 to 0z B (5.5¿6.5 min). Typical conditions for elution of the other samples were as follows: 0 to 100z B (0.0¿1.0 min); 100z B (1.0¿ 3.0 min); and 100 to 0z B (3.0¿4.0 min).
Kinetic analysis: The concentrations of both substrates and inhibitors used for the determination of the Ki value for individual drug oxidations catalyzed by human CYP enzymes are summarized in Table 2 . Kinetic parameters were calculated from theˆtted curves using SigmaPlot 2001 software with Enzyme Kinetic Module 1.1 (SPSS Inc., Chicago, IL, USA).
Results
Inhibitory eŠects of ABT, SKF-525A, and ketoconazole were determined using the microsomes of insect a) Ki values (mean±SE) and b) inhibitory type were determined from a nonlinear regressionˆt of the data set (n is more than three) using the computational program (SigmaPlot 2001 with Enzyme Kinetic Module 1.1, SPSS Inc.). c) a is the factor by which Km changes when inhibitor occupies the enzymes.
d) The inhibitory eŠect was weak, as the details are shown in Fig. 3 . cells infected with bacurovirus containing human CYP and rabbit NADPH-CYP reductase cDNA inserts. To investigate the speciˆc activity for each CYP isoform in the inhibition study, substrate concentrations should set up to be close to the Km values in all activities. Therefore, the kinetic parameters, namely Km and Vmax values, were determined ( Table 3) . The Km values were as follows; CYP1A2, Km＝62 mM for phenacetin Odeethylation; CYP2C9, Km＝2.6 mM for diclofenac 4?-hydroxylation; CYP2C19, Km＝20 mM for Smephenytoin 4?-hydroxylation; CYP2D6, Km＝3.4 mM for bufuralol 1?-hydroxylation; CYP2E1, Km＝65 mM for chlorzoxazone 6-hydroxylation; CYP3A4, Km＝ 34 mM for testosterone 6b-hydroxylation; CYP3A4, Km＝1.8 mM for midazolam 1?-hydroxylation; and CYP3A4, Km＝3.2 mM for nifedipine oxidation. These results were almost equivalent to the reported values except for CYP1A2. The Km value for CYP1A2 used in this study was slightly higher than reported values.
In an inhibition study, the Ki value is a better parameter for deˆning the interaction of an inhibitor with a particular enzyme. Thus, the Ki values and inhibition types (competitive, non-competitive, uncompetitive, or mixed) were determined for ABT, SKF-525A, and ketoconazole on the drug oxidations catalyzed by human CYP enzymes. The results are summarized in Table 4 .
ABT exhibited mixed inhibition of competitive and noncompetitive for all tested drug oxidation; CYP1A2, Ki＝330 mM for phenacetin O-deethylation (a＝1.7); CYP2C9, Ki＝3500 mM for diclofenac 4?-hydroxylation (a＝0.18); CYP2C19, Ki＝110 mM for S-mephenytoin 4?-hydroxylation (a＝0.72); CYP2D6, Ki＝13 mM for bufuralol 1?-hydroxylation (a＝3.5); CYP2E1, Ki＝ 8.7 mM for chlorzoxazone 6-hydroxylation (a＝1.2); CYP3A4, Ki＝1.9 mM for testosterone 6b-hydroxylation (a＝1.6); CYP3A4, Ki＝8.4 mM for midazolam 1?-hydroxylation (a＝1.4); and CYP3A4, Ki＝1.5 mM for nifedipine oxidation (a＝1.9). The Ki value for CYP2C9-dependent diclofenac 4?-hydroxylation was the highest among those determined in this assay. With the respect to CYP3A4-dependent drug oxidations, the Ki value of ABT for midazolam 1?-hydroxylation was the highest of those for investigated three drug oxidations (Fig. 2) .
SKF-525A weakly inhibited CYP1A2-dependent activities and CYP2E1-dependent activities (Fig. 3) . However, SKF-525A competitively inhibited CYP2C9-dependent diclofenac 4?-hydroxylation (Ki＝10 mM), CYP2C19-dependent S-mephenytoin 4?-hydroxylation (Ki＝1.0 mM), and CYP3A4-dependent midazolam 1?-hydroxylation (Ki＝1.2 mM). The inhibition for CYP2D6-dependent bufuralol 1?-hydroxylation (Ki＝ 0.043 mM, a＝21) and CYP3A4-dependent testosterone 6b-hydroxylation (Ki＝0.79 mM, a＝2.9) and nifedipine oxidation (Ki＝4.2 mM, a＝4.0) was a mixed-type of 
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In vitro Inhibitory EŠect of 1-Aminobenzotriazole on Drug Oxidations competitive and noncompetitive inhibition. In the drug oxidation catalyzed by CYP2C subfamilies, the Ki value of SKF-525A for CYP2C19-dependent S-mephenytoin 4-hydroxylation was much lower than that for CYP2C9-dependent diclofenac 4?-hydroxylation (Fig. 4) .
Ketoconazole inhibited all tested drug oxidations catalyzed by the CYP enzymes. Ketoconazole weakly inhibited CYP1A2-dependent activities (50z inhibition at 120 mM, Fig. 3A) . As far as CYP2C subfamilies, ketoconazole exhibited competitive inhibition. The Ki values were 7.9 mM for CYP2C9-dependent diclofenac 4?-hydroxylation and 6.9 mM for CYP2C19-dependent S-mephenytoin 4?-hydroxylation. Ketoconazole exhibited mixed inhibition for CYP2D6-dependent bufuralol 1?-hydroxylation (Ki＝12 mM, a＝7.6), CYP2E1-dependent chlorzoxazone 6-hydroxylation (Ki＝41 mM, a＝ 0.73), CYP3A4-dependent testosterone 6b-hydroxylation (Ki＝0.024 mM, a＝8.8), and CYP3A4-dependent nifedipine oxidation (Ki＝0.011 mM, a＝32). Ketoconazole competitively inhibited CYP3A4-dependent midazolam 1?-hydroxylation (Ki＝0.028 mM). The Ki values of ketoconazole for CYP3A4-dependent drug oxidations were much lower than those for the other drug oxidations.
Discussion
CYP enzymes play an important role in drug oxidation, which is one of the major clearance process for the body.
3) Therefore, in the drug development process, it is useful to predict the contribution of CYP enzymes to the metabolism of certain compounds. ABT is widely used as a non-speciˆc CYP inhibitor because it is known to be a suicide substrate for CYP isoforms. It was reported that benzyne, which was formed from ABT, forms an N,N-bridged benzyne-protoporphyrin IX adduct in rats. 4, 11) However, selectivity of ABT for inhibition of drug oxidations catalyzed by human CYP enzymes has not been investigated. Therefore, the inhibitory eŠect of ABT on drug oxidation catalyzed by several human CYP isoforms was investigated and com-pared with SKF-525A, a non-speciˆc CYP inhibitors, 12) and ketoconazole, the CYP3A-selective inhibitor. 13) At rst, their direct inhibitory eŠects were investigated. The inhibitory eŠects of ABT on both CYP1A2-and CYP2E1-dependent drug oxidations were contrary to those of SKF-525A. Moreover, ABT exhibited the highest Ki value for CYP2C9-dependent diclofenac 4?-hydroxylation among those determined in this assay (Ki ＝3500 mM). Ketoconazole inhibited all the investigated drug oxidations, however, its inhibitory eŠect on CYP1A2-dependent activities was very weak. These results indicated that the selectivity for CYP isoforms is diŠerent for these CYP inhibitors. With respect to the inhibitory eŠects of ABT and SKF-525A on CYP2C-dependent drug oxidation, Huang and Waxman reported that, in rat liver microsomes, CYP2C-dependent cyclophosphamide 4-hydroxylation was inhibited to 60z by 50 mM ABT but to 80z by 10 mM SKF-525A. 14) According to this reference, the ABT was preincubated with rat liver microsomes for 15 minutes before being added to the reaction mixture; however, the SKF-525A was added directly to the reaction mixture. In the present study, both ABT and SKF-525A were added to the reaction mixture without preincubation in the presence of NADPH. From these data, the inhibitory eŠects of SKF-525A on CYP2C-dependent drug oxidation were observed in rat liver microsomes as well as human recombinant CYP2C9 microsomes without preincubation in the presence of NADPH. In contrast, the degree of inhibition by ABT in human recombinant CYP2C9 was diŠerent from that in rat liver microsomes. This diŠerence might be attributed to the preincubation of ABT in the presence of NADPH and W or the diŠerences in a‹nity of CYP2C substrates and ABT for CYP2C enzymes in rat and human.
Schenkman et al. reported that SKF-525A competitively inhibits both aminopyrine demethylation and aniline hydroxylation in rat liver microsomes; however, the inhibition type becomes non-competitive when these microsomes are preincubated with SKF-525A in the presence of NADPH.
15) The authors suggested that both SKF-525A and its metabolites are inhibitors for drug oxidations. 15) Aminopyrine N-demethylation was catalyzed by CYP2C11 in rat and CYP2C19 and CYP2B6 in human. 16, 17) In this study, SKF-525A exhibited competitive inhibition for CYP2C-dependent activities. The inhibitory eŠect of SKF-525A for CYP2C-dependent activities might be caused not by the SKF-525A metabolites but by SKF-525A itself.
Ketoconazole inhibited all tested drug oxidations, however, ketoconazole very weakly inhibited CYP1A2-dependent activities (50z inhibition at 120 mM) in this study using recombinant CYP microsomes. From the results, ketoconazole was classiˆed into three class: potent inhibitor for CYP3A-dependent activities (Ki, less than 2 mM); moderate for CYP2C-and CYP2D-dependent activities (5 mMºKiº15 mM); and relatively weak for CYP1A2-and CYP2E1-depandent activities (Ki, more than 15 mM). Maurice et al. reported that ketoconazole is a very weak inhibitor for CYP1A2-dependent phenacetin O-deethylation in human liver microsomes. 18) With respect to CYP2C-dependent activities, it was reported that ketoconazole inhibited CYP2C9-dependent tolbutamide 4-hydroxylation (Ki＝ 8 mM) and CYP2C19-dependent S-mephenytoin 4?-hydroxylation (Ki＝31 mM) in human liver microsomes. 19, 20) In addition, CYP2D6-dependent desipramine 2-hydroxylation was inhibited by ketoconazole in human liver microsomes (Ki＝10.3 mM).
21) According to Newton et al., ketoconazole inhibited CYP1A2-dependent phenacetin O-deethylation and CYP2E1-depandent chlorzoxazone 6-hydroxylation by 30-50z at 100 mM, CYP2D6-dependent bufuralol 1?-hydroxylation and CYP2C9-dependent tolbutamide 4-hydroxylation by 80z, and CYP3A4-dependent testosterone 6b-hydroxylation by 90z in human liver microsomes. 22) The results in recombinant CYP microsomes were almost equivalent to those in human liver microsomes.
ABT, SKF-525A, and ketoconazole showed diŠerent selectivity with a wide range of Ki values for drug oxidations catalyzed by CYP enzymes. These results suggest that an inhibitory study to predict the contribution of CYP enzymes to the metabolism of compounds should be performed using multiple CYP inhibitors such as those chosen in this study. Additionally, both ABT and SKF-525A are known as mechanism-based inhibitors. Therefore, in our laboratory, we have endeavored to clarify the eŠect of preincubation by ABT and SKF-525A on drug oxidation catalyzed by human CYP enzymes.
